Decade of growth predicted for Fabry disease market in USA and Japan

25 June 2021

The Fabry disease (FD) market in the USA and Japan will see significant expansion between 2020 and 2030, as total sales in the two markets are set to rise from $820.15 million in 2020 to $985.81 million in 2030, at a compound annual growth rate (CAGR) of 1.9%.

This sales growth will be in line with a steadily increasing disease prevalence and the entrance of new agents into the market, according to data and analytics company GlobalData.

Several drugs in the pipeline have novel mechanisms of action (MoAs), including gene therapies that offer the promise of single-dose and potentially curative therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK